Breathe Easy: Meeting the Preclinical Challenges of Pulmonary Fibrosis

The race is on for better therapies to treat pulmonary fibrosis, a chronic lung disease characterized by irreversible scarring of lung tissue. Though the condition is classified as a rare disease, its impact on patients is profound: nearly as many Americans die each year from the most common form of the disease, idiopathic pulmonary fibrosis (IPF), as from breast cancer.

Lovelace Biomedical Featured in The Scientist: Why Pharma Should Consider Canine Models for Alzheimer’s

Dr. Barrett explains the drug industry’s challenge to meet clinical endpoints for Alzheimer’s therapies that have shown promise in mice: “Despite researchers’ valiant efforts to stall, slow, or even beat this devastating neurodegenerative condition, there are still no effective drugs available to the estimated 5.4 million Americans with the disease.”

The Quality Guru: 5 Questions With Lovelace’s Jen Cleerdin

At Lovelace Biomedical, the essential functions of compliance and quality assurance are spearheaded by the passionate Jennifer Cleerdin, Senior Director of Scientific Operations. Since joining Lovelace in 2003, Ms. Cleerdin has developed and implemented a quality process that’s unparalleled in the contract research field.

Lovelace Biomedical’s Advances in Toxicological Research to be Featured at the 56th Annual Meeting of the Society of Toxicology

Albuquerque, N.M., March 8, 2017 – Lovelace Biomedical, a not-for-profit preclinical contract research organization, today announced its participation in and presentation of scientific data at the Society of Toxicology (SOT) 56th Annual Meeting, held March 12 to 16 in Baltimore. This announcement comes on the heels of launching Lovelace Biomedical to partner with companies to cost-effectively and efficiently advance preclinical development of therapeutic compounds and novel technologies, highlighting its shift in focus and expertise in general and specialty toxicology.

Diving Deep into General Toxicology: 5 Questions with Dr. Matthew Reed

As Lovelace Biomedical expands its footprint in toxicology service offerings, some are asking: Why general toxicology, and why now? Here, we get the answers from Dr. Matthew Reed, a board-certified toxicologist and Lovelace’s Vice President of Applied Toxicology and Nonclinical Development

A Rich History, An Exciting Future

As you prepare to launch ambitious new projects in 2017, I’d like to personally encourage you to explore the wide array of services and expertise Lovelace Biomedical provides in toxicology, pharmacology, formulation and more. While Lovelace is the same not-for-profit CRO you’ve always known—with a deep history of excellence in respiratory research—today, we offer much more.